Compare Boston Scientific Corporation (BSX) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Boston Scientific Corporation trades at $51.07 (market cap $74.19B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.22. Which is the better fit depends on your goals.
| BSX | LQD | |
|---|---|---|
Market Cap | $74.19B | — |
Sector | Health | — |
52-Week High | $108.14 | $112.91 |
52-Week Low | $42.63 | $105.96 |
Enterprise Value | $86.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
LQD, the iShares iBoxx $ Investment Grade Corporate Bond ETF, trades at $106.335, up 0.35% today, while technical indicators signal a bearish trend with moving averages and key oscillators in sell or neutral territory. The ETF has declared several dividends for 2026, with payments scheduled through August, reflecting its income-focused strategy amid fluctuating bond markets driven by inflation fears and geopolitical tensions.
The outlook for LQD is cautious due to bearish technicals and macroeconomic pressures like rising oil prices and potential Fed rate hikes, which could pressure corporate bond yields. Investors may find value in its investment-grade corporate debt exposure for diversification, but must monitor interest rate volatility and economic data closely for risks to fixed income returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
